February 15th, 2018 08:00

Immunovia Full Year report, January-December 2017

“The fourth quarter of 2017 marked an important inflection point for Immunovia in many aspects. We ended our final year of purely pre-commercial activity, and have now started what is planned as our first business year that will lead to the start of sales in the second half of 2018.” “During 2018 we expect to reach our target of starting commercial sales of IMMray™  PanCan –dby providing the test to customers, both private individuals and health organizations, so-calledself-pay customers.” “The internal work aimed at preparing the company for a listing on Nasdaq Stockholm’s main market was completed in 2017. We have submitted our application and we are expecting to receive a decision in the first quarter of 2018.” Mats Grahn, CEO, Immunovia.

Key Indicators

Key Indicators
(SEK 000 unless otherwise stated)
1 Oct-31 Dec 2017 1 Oct-31 dec 2016 Full year 2017 Full year 2016
Net sales 26 106 149 177
Operating earnings -15,362 -5,527 -45,520 -14,978
Earnings before tax -15,318 -5,377 -45,232 -14,723
Net earnings -15,318 -5,377 -45,232 -14,723
Earnings per share before dilution (SEK/share) -0,88 -0,32 -2,67 -0,98
Equity ratio, % 94 98 94 98
No. of shares at the end of the period 17,318,059  16,804,059 17,318,059  16,804,059

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiary Immunovia Inc.

Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray is a technology platform for the development of diagnostic tests and the company’s primary test. IMMray PanCan-d is the first test in the world for early diagnosis of pancreatic cancer.

 • It is planned to launch IMMray™ PanCan-d on the American and European markets with sales to selfpay-customers, to start when the accreditation and production upscaling have been completed, with revenues expected to begin in 2018. In coming years Immunovia will address a market that in total is worth around SEK 35 billion.

• Immunovia sees great potential in the development of tests for other unsolved problems in cancer and autoimmune diseases via its IMMray™ platform. The next focus area will be tests within SLE, based on the positive results announced in early 2017.

For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray® , is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray®  PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer.  In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray®  SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.